AAV gene therapy with vectors encoding glucose 6-phosphatase (G6Pase), which is an enzyme that hydrolyzes glucose 6-phosphate, reversed underlying hepatocellular abnormalities in dogs with glycogen storage disease (GSD) type Ia.58 This evidence concerns the gene G6PC1 and disorder of glycogen metabolism.